# name
MOG Antibodies Restricted to CSF in Children With Inflammatory CNS Disorders

# metadata.dc.description.abstract[].value
Objectives
To assess the clinical significance of myelin oligodendrocyte glycoprotein antibodies (MOG-abs)
restricted to CSF in children with inflammatory CNS disorders.
Methods
Patients included 760 children (younger than 18 years) from 3 multicenter prospective cohort
studies: (A) acquired demyelinating syndromes, including acute disseminated encephalomy-
elitis (ADEM); (B) non-ADEM encephalitis; and (C) noninflammatory neurologic disorders.
For all cases, paired serum/CSF samples were systematically examined using brain immuno-
histochemistry and live cell-based assays.
Results
A total of 109 patients (14%) had MOG-abs in serum or CSF: 79 from cohort A, 30 from B, and
none from C. Of these, 63 (58%) had antibodies in both samples, 37 (34%) only in serum, and 9
(8%) only in CSF. Children with MOG-abs only in CSF were older than those with MOG-abs
only in serum or in both samples (median 12 vs 6 vs 5 years, p = 0.0002) and were more likely to
have CSF oligoclonal bands (86% vs 12% vs 7%, p = 0.0001) and be diagnosed with multiple
sclerosis (6/9 [67%] vs 0/37 [0%] vs 1/63 [2%], p < 0.0001).
Discussion
Detection of MOG-abs in serum or CSF is associated with CNS inflammatory disorders.
Children with MOG-abs restricted to CSF are more likely to have CSF oligoclonal bands and
multiple sclerosis than those with MOG-abs detectable in serum.

# metadata.dc.publisher[].value
Lippincott, Williams & Wilkins. Wolters Kluwer Health

# metadata.dc.source[].value
Articles publicats en revistes (Medicina)

# metadata.dc.title[].value
MOG Antibodies Restricted to CSF in Children With Inflammatory CNS Disorders